Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

IF 2.8 4区 医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-10-14 DOI:10.1007/s12032-024-02529-9
Saade Abdalkareem Jasim, Abdulrahman T Ahmed, Aziz Kubaev, Ashishkumar Kyada, Mohammad Y Alshahrani, Shilpa Sharma, Hussein Riyadh Abdul Kareem Al-Hetty, Raghav Vashishth, Ashish Singh Chauhan, Munther Kadhim Abosaoda
{"title":"Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.","authors":"Saade Abdalkareem Jasim, Abdulrahman T Ahmed, Aziz Kubaev, Ashishkumar Kyada, Mohammad Y Alshahrani, Shilpa Sharma, Hussein Riyadh Abdul Kareem Al-Hetty, Raghav Vashishth, Ashish Singh Chauhan, Munther Kadhim Abosaoda","doi":"10.1007/s12032-024-02529-9","DOIUrl":null,"url":null,"abstract":"<p><p>MicroRNAs (miRNAs) are conserved non-protein-coding RNAs that are naturally present in organisms and can control gene expression by suppressing the translation of mRNA or causing the degradation of mRNA. MicroRNAs are highly concentrated in the PI3K/AKT pathway, and abnormal activation of the PI3K/AKT pathway plays a role in cancer progression. The AKT/PI3K pathway is critical for cellular functions and can be stimulated by cytokines and in normal situations. It is involved in regulating various intracellular signal transduction, including development, differentiation, transcriptional regulation, protein, and synthesis. There is a growing body of evidence indicating that miRNAs, which are abundant in exosomes released by different cells, can control cellular biological activities via modulating the PI3K/AKT pathway, hence influencing cancer progression and drug resistance. This article provides an overview of the latest research progress regarding the function and medical use of the PI3K/AKT pathway and exosomal miRNA/AKT/PI3K axis in the behaviors of cancer cells.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02529-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

MicroRNAs (miRNAs) are conserved non-protein-coding RNAs that are naturally present in organisms and can control gene expression by suppressing the translation of mRNA or causing the degradation of mRNA. MicroRNAs are highly concentrated in the PI3K/AKT pathway, and abnormal activation of the PI3K/AKT pathway plays a role in cancer progression. The AKT/PI3K pathway is critical for cellular functions and can be stimulated by cytokines and in normal situations. It is involved in regulating various intracellular signal transduction, including development, differentiation, transcriptional regulation, protein, and synthesis. There is a growing body of evidence indicating that miRNAs, which are abundant in exosomes released by different cells, can control cellular biological activities via modulating the PI3K/AKT pathway, hence influencing cancer progression and drug resistance. This article provides an overview of the latest research progress regarding the function and medical use of the PI3K/AKT pathway and exosomal miRNA/AKT/PI3K axis in the behaviors of cancer cells.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为人类肿瘤中 PI3K/AKT 通路关键调节因子的外泌体 microRNA。
微RNA(miRNA)是生物体内天然存在的保守的非蛋白编码RNA,可通过抑制mRNA翻译或导致mRNA降解来控制基因表达。微RNA高度集中在PI3K/AKT通路中,而PI3K/AKT通路的异常激活在癌症进展中起着作用。AKT/PI3K 通路对细胞功能至关重要,在正常情况下可受到细胞因子的刺激。它参与调节各种细胞内信号转导,包括发育、分化、转录调节、蛋白质和合成。越来越多的证据表明,不同细胞释放的外泌体中含量丰富的 miRNA 可通过调节 PI3K/AKT 通路控制细胞的生物活性,从而影响癌症的进展和耐药性。本文概述了有关 PI3K/AKT 通路和外泌体 miRNA/AKT/PI3K 轴在癌细胞行为中的功能和医学应用的最新研究进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
期刊最新文献
ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology. CAP superfamily proteins in human: a new target for cancer therapy. Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality". Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1